EphB receptors trigger Akt activation and suppress fas receptor-induced apoptosis in malignant T lymphocytes

Journal of Immunology

Volumn 187, Issue 11, 2011, Pages 5983-5994

  Maddigan, Alison ^a   Truitt, Luke ^b   Arsenault, Ryan ^b   Freywald, Tanya ^b   Allonby, Odette ^b   Dean, Jonathan ^a   Narendran, Aru ^c   Xiang, Jim ^d   Weng, Andrew ^e   Napper, Scott ^b   Freywald, Andrew ^b  

^a UNIVERSITY OF REGINA   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

^c ALBERTA CHILDREN'S HOSPITAL   (Canada)

^d UNIVERSITY OF SASKATCHEWAN   (Canada)

^e BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE; EPHRIN B1; EPHRIN B2; EPHRIN RECEPTOR B3; EPHRIN RECEPTOR B6; FAS ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PROTEIN KINASE B; PROTEIN TYROSINE KINASE;

ACUTE LYMPHOBLASTIC LEUKEMIA; APOPTOSIS; ARTICLE; CANCER INVASION; CELL PROTECTION; CELL SURVIVAL; CONTROLLED STUDY; CYTOLOGY; CYTOTOXIC T LYMPHOCYTE; ENZYME ACTIVATION; ENZYME INHIBITION; GRAFT VERSUS LEUKEMIA EFFECT; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; RECEPTOR BLOCKING; T CELL LEUKEMIA;

ANTIGENS, CD95; APOPTOSIS; CELL SEPARATION; ENZYME ACTIVATION; FLOW CYTOMETRY; HUMANS; LEUKEMIA, T-CELL; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTORS, EPH FAMILY; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; T-LYMPHOCYTES; TUMOR ESCAPE;

EID: 82755187672     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1003482     Document Type: Article

References (85)

1. Van Vlierberghe, P., R. Pieters, H. B. Beverloo, and J. P. Meijerink. 2008. Molecular-genetic insights in paediatric T-cell acute lymphoblastic leukaemia. Br. J. Haematol. 143: 153-168.
2. Klemke, C. D., S. Goerdt, D. Schrama, and J. C. Becker. 2006. New insights into the molecular biology and targeted therapy of cutaneous T-cell lymphomas. J. Dtsch. Dermatol. Ges. 4: 395-406.
3. Herman, J. G., J. Jen, A. Merlo, and S. B. Baylin. 1996. Hypermethylationassociated inactivation indicates a tumor suppressor role for p15INK4B. Cancer Res. 56: 722-727.
4. Okamoto, A., D. J. Demetrick, E. A. Spillare, K. Hagiwara, S. P. Hussain, W. P. Bennett, K. Forrester, B. Gerwin, M. Serrano, D. H. Beach, et al. 1994. Mutations and altered expression of p16INK4 in human cancer. Proc. Natl. Acad. Sci. USA 91: 11045-11049.
5. Merlo, A., J. G. Herman, L. Mao, D. J. Lee, E. Gabrielson, P. C. Burger, S. B. Baylin, and D. Sidransky. 1995. 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat. Med. 1: 686-692.
6. Weng, A. P., A. A. Ferrando, W. Lee, J. P. Morris, IV, L. B. Silverman, C. Sanchez-Irizarry, S. C. Blacklow, A. T. Look, and J. C. Aster. 2004. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 306: 269-271. (Pubitemid 39336870)
7. Weng, A. P., and A. Lau. 2005. Notch signaling in T-cell acute lymphoblastic leukemia. Future Oncol. 1: 511-519.
8. Thompson, B. J., S. Buonamici, M. L. Sulis, T. Palomero, T. Vilimas, G. Basso, A. Ferrando, and I. Aifantis. 2007. The SCFFBW7 ubiquitin ligase complex as a tumor suppressor in T cell leukemia. J. Exp. Med. 204: 1825-1835. (Pubitemid 47236320)
9. Malyukova, A., T. Dohda, N. von der Lehr, S. Akhoondi, M. Corcoran, M. Heyman, C. Spruck, D. Grandér, U. Lendahl, and O. Sangfelt. 2007. The tumor suppressor gene hCDC4 is frequently mutated in human T-cell acute lymphoblastic leukemia with functional consequences for Notch signaling. [Published erratum appears in 2008 Cancer Res. 68: 2051.] Cancer Res. 67: 5611-5616. (Pubitemid 46984990)
10. O'Neil, J., J. Grim, P. Strack, S. Rao, D. Tibbitts, C. Winter, J. Hardwick, M. Welcker, J. P. Meijerink, R. Pieters, et al. 2007. FBW7 mutations in leukemic cells mediate NOTCH pathway activation and resistance to gamma-secretase inhibitors. J. Exp. Med. 204: 1813-1824. (Pubitemid 47236319)
11. Palomero, T., M. L. Sulis, M. Cortina, P. J. Real, K. Barnes, M. Ciofani, E. Caparros, J. Buteau, K. Brown, S. L. Perkins, et al. 2007. Mutational loss of PTEN induces resistance to NOTCH1 inhibition in T-cell leukemia. Nat. Med. 13: 1203-1210. (Pubitemid 47530629)
12. Sterry, W. 2007. Cutaneous T-cell lymphoma: molecular and cytogenetic findings. Oncology (Williston Park) 21(2 Suppl. 1): 13-17.
13. Sommer, V. H., O. J. Clemmensen, O. Nielsen, M. Wasik, P. Lovato, C. Brender, K. W. Eriksen, A. Woetmann, C. G. Kaestel, M. H. Nissen, et al. 2004. In vivo activation of STAT3 in cutaneous T-cell lymphoma. Evidence for an antiapoptotic function of STAT3. Leukemia 18: 1288-1295. (Pubitemid 39023140)
14. Notohamiprodjo,M., S. Segerer, R. Huss, B. Hildebrandt, D. Soler, R. Djafarzadeh, W. Buck, P. J. Nelson, and I. von Luettichau. 2005. CCR10 is expressed in cutaneous T-cell lymphoma. Int. J. Cancer 115: 641-647. (Pubitemid 40656724)
15. Mao, X., G. Orchard, D. M. Lillington, R. Russell-Jones, B. D. Young, and S. J. Whittaker. 2003. Amplification and overexpression of JUNB is associated with primary cutaneous T-cell lymphomas. Blood 101: 1513-1519. (Pubitemid 36182528)
16. Zhang, C. L., J. Kamarashev, J. Z. Qin, G. Burg, R. Dummer, and U. Döbbeling. 2003. Expression of apoptosis regulators in cutaneous T-cell lymphoma (CTCL) cells. J. Pathol. 200: 249-254. (Pubitemid 36748034)
17. Blair, A., N. J. Goulden, N. A. Libri, A. Oakhill, and D. H. Pamphilon. 2005. Immunotherapeutic strategies in acute lymphoblastic leukaemia relapsing after stem cell transplantation. Blood Rev. 19: 289-300. (Pubitemid 41571930)
18. Palomero, T., and A. Ferrando. 2009. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia. Clin. Lymphoma Myeloma 9 (Suppl. 3): S205-S210.
19. Gardner, J. M., K. G. Evans, A. Musiek, A. H. Rook, and E. J. Kim. 2009. Update on treatment of cutaneous T-cell lymphoma. Curr. Opin. Oncol. 21: 131-137.
20. Ringdén, O., H. Karlsson, R. Olsson, B. Omazic, and M. Uhlin. 2009. The allogeneic graft-versus-cancer effect. Br. J. Haematol. 147: 614-633.
21. Schetelig, J., A. Kiani, M. Schmitz, G. Ehninger, and M. Bornhäuser. 2005. T cell-mediated graft-versus-leukemia reactions after allogeneic stem cell transplantation. Cancer Immunol. Immunother. 54: 1043-1058. (Pubitemid 41396810)
22. Frey, A. B., and N. Monu. 2008. Signaling defects in anti-tumor T cells. Immunol. Rev. 222: 192-205. (Pubitemid 351430368)
23. Chávez-Galán, L., M. C. Arenas-Del Angel, E. Zenteno, R. Chávez, and R. Lascurain. 2009. Cell death mechanisms induced by cytotoxic lymphocytes. Cell. Mol. Immunol. 6: 15-25.
24. Meech, S. J., R. Edelson, P. Walsh, D. A. Norris, and R. C. Duke. 2001. Reversible resistance to apoptosis in cutaneous T cell lymphoma. Ann. N. Y. Acad. Sci. 941: 46-58. (Pubitemid 32928333)
25. Fang, W. B., D. M. Brantley-Sieders, M. A. Parker, A. D. Reith, and J. Chen. 2005. A kinase-dependent role for EphA2 receptor in promoting tumor growth and metastasis. Oncogene 24: 7859-7868. (Pubitemid 41715192)
26. Kumar, S. R., J. S. Scehnet, E. J. Ley, J. Singh, V. Krasnoperov, R. Liu, P. K. Manchanda, R. D. Ladner, D. Hawes, F. A. Weaver, et al. 2009. Preferential induction of EphB4 over EphB2 and its implication in colorectal cancer progression. Cancer Res. 69: 3736-3745.
27. Kumar, S. R., R. Masood, W. A. Spannuth, J. Singh, J. Scehnet, G. Kleiber, N. Jennings, M. Deavers, V. Krasnoperov, L. Dubeau, et al. 2007. The receptor tyrosine kinase EphB4 is overexpressed in ovarian cancer, provides survival signals and predicts poor outcome. Br. J. Cancer 96: 1083-1091. (Pubitemid 46608305)
28. Masood, R., S. R. Kumar, U. K. Sinha, D. L. Crowe, V. Krasnoperov, R. K. Reddy, S. Zozulya, J. Singh, G. Xia, D. Broek, et al. 2006. EphB4 provides survival advantage to squamous cell carcinoma of the head and neck. Int. J. Cancer 119: 1236-1248. (Pubitemid 44258795)
29. Xia, G., S. R. Kumar, R. Masood, M. Koss, C. Templeman, D. Quinn, S. Zhu, R. Reddy, V. Krasnoperov, and P. S. Gill. 2005. Up-regulation of EphB4 in mesothelioma and its biological significance. Clin. Cancer Res. 11: 4305-4315. (Pubitemid 40825617)
30. Xia, G., S. R. Kumar, R. Masood, S. Zhu, R. Reddy, V. Krasnoperov, D. I. Quinn, S. M. Henshall, R. L. Sutherland, J. K. Pinski, et al. 2005. EphB4 expression and biological significance in prostate cancer. Cancer Res. 65: 4623-4632. (Pubitemid 40740798)
31. Pasquale, E. B. 2010. Eph receptors and ephrins in cancer: bidirectional signalling and beyond. Nat. Rev. Cancer 10: 165-180.
32. Gale, N. W., S. J. Holland, D. M. Valenzuela, A. Flenniken, L. Pan, T. E. Ryan, M. Henkemeyer, K. Strebhardt, H. Hirai, D. G. Wilkinson, et al. 1996. Eph receptors and ligands comprise two major specificity subclasses and are reciprocally compartmentalized during embryogenesis. Neuron 17: 9-19. (Pubitemid 26251587)
33. Gale, N. W., A. Flenniken, D. C. Compton, N. Jenkins, N. G. Copeland, D. J. Gilbert, S. Davis, D. G. Wilkinson, and G. D. Yancopoulos. 1996. Elk-L3, a novel transmembrane ligand for the Eph family of receptor tyrosine kinases, expressed in embryonic floor plate, roof plate and hindbrain segments. Oncogene 13: 1343-1352. (Pubitemid 26343588)
34. Blits-Huizinga, C. T., C. M. Nelersa, A. Malhotra, and D. J. Liebl. 2004. Ephrins and their receptors: binding versus biology. IUBMB Life 56: 257-265. (Pubitemid 39272989)
35. Himanen, J. P., M. J. Chumley, M. Lackmann, C. Li, W. A. Barton, P. D. Jeffrey, C. Vearing, D. Geleick, D. A. Feldheim, A. W. Boyd, et al. 2004. Repelling class discrimination: ephrin-A5 binds to and activates EphB2 receptor signaling. Nat. Neurosci. 7: 501-509. (Pubitemid 38544589)
36. Qin, H., R. Noberini, X. Huan, J. Shi, E. B. Pasquale, and J. Song. 2010. Structural characterization of the EphA4-Ephrin-B2 complex reveals new features enabling Eph-ephrin binding promiscuity. J. Biol. Chem. 285: 644-654.
37. Freywald, A., N. Sharfe, and C. M. Roifman. 2002. The kinase-null EphB6 receptor undergoes transphosphorylation in a complex with EphB1. J. Biol. Chem. 277: 3823-3828. (Pubitemid 34968631)
38. Munthe, E., E. Rian, T. Holien, A. Rasmussen, F. O. Levy, and H. Aasheim. 2000. Ephrin-B2 is a candidate ligand for the Eph receptor, EphB6. FEBS Lett. 466: 169-174. (Pubitemid 30050706)
39. Kullander, K., and R. Klein. 2002. Mechanisms and functions of Eph and ephrin signalling. Nat. Rev. Mol. Cell Biol. 3: 475-486. (Pubitemid 34733429)
40. Himanen, J. P., N. Saha, and D. B. Nikolov. 2007. Cell-cell signaling via Eph receptors and ephrins. Curr. Opin. Cell Biol. 19: 534-542. (Pubitemid 350016850)
41. Pasquale, E. B. 2005. Eph receptor signalling casts a wide net on cell behaviour. Nat. Rev. Mol. Cell Biol. 6: 462-475. (Pubitemid 40780558)
42. Pasquale, E. B. 2008. Eph-ephrin bidirectional signaling in physiology and disease. Cell 133: 38-52. (Pubitemid 351442996)
43. Genander, M., and J. Frisén. 2010. Ephrins and Eph receptors in stem cells and cancer. Curr. Opin. Cell Biol. 22: 611-616.
44. Kuang, S. Q., H. Bai, Z. H. Fang, G. Lopez, H. Yang, W. Tong, Z. Z. Wang, and G. Garcia-Manero. 2010. Aberrant DNA methylation and epigenetic inactivation of Eph receptor tyrosine kinases and ephrin ligands in acute lymphoblastic leukemia. Blood 115: 2412-2419.
45. Sharfe, N., M. Nikolic, L. Cimpeon, A. Van De Kratts, A. Freywald, and C. M. Roifman. 2008. EphA and ephrin-A proteins regulate integrin-mediated T lymphocyte interactions. Mol. Immunol. 45: 1208-1220. (Pubitemid 350299492)
46. Sharfe, N., A. Freywald, A. Toro, and C. M. Roifman. 2003. Ephrin-A1 induces c-Cbl phosphorylation and EphA receptor down-regulation in T cells. J. Immunol. 170: 6024-6032. (Pubitemid 36682583)
47. Smith, L. M., P. T. Walsh, T. Rüdiger, T. G. Cotter, T. V. Mc Carthy, A. Marx, and R. O'Connor. 2004. EphA3 is induced by CD28 and IGF-1 and regulates cell adhesion. Exp. Cell Res. 292: 295-303. (Pubitemid 38018845)
48. Alonso-C, L. M., E. M. Trinidad, B. de Garcillan, M. Ballesteros, M. Castellanos, I. Cotillo, J. J. Muñoz, and A. G. Zapata. 2009. Expression profile of Eph receptors and ephrin ligands in healthy human B lymphocytes and chronic lymphocytic leukemia B-cells. Leuk. Res. 33: 395-406.
49. Shimoyama, M., H. Matsuoka, A. Tamekane, M. Ito, N. Iwata, R. Inoue, K. Chihara, A. Furuya, N. Hanai, and T. Matsui. 2000. T-cell-specific expression of kinase-defective Eph-family receptor protein, EphB6 in normal as well as transformed hematopoietic cells. Growth Factors 18: 63-78. (Pubitemid 30303655)
50. Steube, K. G., C. Meyer, S. Habig, C. C. Uphoff, and H. G. Drexler. 1999. Expression of receptor tyrosine kinase HTK (hepatoma transmembrane kinase) and HTK ligand by human leukemia-lymphoma cell lines. Leuk. Lymphoma 33: 371-376. (Pubitemid 29196875)
51. Jiang, G., T. Freywald, J.Webster, D. Kozan, R. Geyer, J. DeCoteau, A. Narendran, and A. Freywald. 2008. In human leukemia cells ephrin-B-induced invasive activity is supported by Lck and is associated with reassembling of lipid raft signaling complexes. Mol. Cancer Res. 6: 291-305. (Pubitemid 351342417)
52. Trinidad, E. M., M. Ballesteros, J. Zuloaga, A. Zapata, and L. M. Alonso-Colmenar. 2009. An impaired transendothelial migration potential of chronic lymphocytic leukemia (CLL) cells can be linked to ephrin-A4 expression. Blood 114: 5081-5090.
53. Wimmer-Kleikamp, S. H., E. Nievergall, K. Gegenbauer, S. Adikari, M. Mansour, T. Yeadon, A. W. Boyd, N. R. Patani, and M. Lackmann. 2008. Elevated protein tyrosine phosphatase activity provokes Eph/ephrin-facilitated adhesion of pre-B leukemia cells. Blood 112: 721-732.
54. O' Reilly, L. A., L. Tai, L. Lee, E. A. Kruse, S. Grabow, W. D. Fairlie, N. M. Haynes, D. M. Tarlinton, J. G. Zhang, G. T. Belz, et al. 2009. Membranebound Fas ligand only is essential for Fas-induced apoptosis. Nature 461: 659-663.
55. Wu, J., and H. Luo. 2005. Recent advances on T-cell regulation by receptor tyrosine kinases. Curr. Opin. Hematol. 12: 292-297. (Pubitemid 41058393)
56. Luzina, I. G., S. P. Atamas, R. Wise, F. M. Wigley, J. Choi, H. Q. Xiao, and B. White. 2003. Occurrence of an activated, profibrotic pattern of gene expression in lung CD8+ T cells from scleroderma patients. Arthritis Rheum. 48: 2262-2274. (Pubitemid 36959208)
57. Sakamoto, A., H. Ishibashi-Ueda, Y. Sugamoto, T. Higashikata, S. Miyamoto, M. A. Kawashiri, K. Yagi, T. Konno, K. Hayashi, N. Fujino, et al. 2008. Expression and function of ephrin-B1 and its cognate receptor EphB2 in human atherosclerosis: from an aspect of chemotaxis. Clin. Sci. 114: 643-650. (Pubitemid 351589063)
58. Jones, R. G., A. R. Elford, M. J. Parsons, L. Wu, C. M. Krawczyk, W. C. Yeh, R. Hakem, R. Rottapel, J. R. Woodgett, and P. S. Ohashi. 2002. CD28-dependent activation of protein kinase B/Akt blocks Fas-mediated apoptosis by preventing death-inducing signaling complex assembly. J. Exp. Med. 196: 335-348. (Pubitemid 34875663)
59. Barnhart, B. C., E. C. Alappat, and M. E. Peter. 2003. The CD95 type I/type II model. Semin. Immunol. 15: 185-193. (Pubitemid 38155825)
60. Fox, B. P., and R. P. Kandpal. 2004. Invasiveness of breast carcinoma cells and transcript profile: Eph receptors and ephrin ligands as molecular markers of potential diagnostic and prognostic application. Biochem. Biophys. Res. Commun. 318: 882-892. (Pubitemid 38625856)
61. Fox, B. P., and R. P. Kandpal. 2006. Transcriptional silencing of EphB6 receptor tyrosine kinase in invasive breast carcinoma cells and detection of methylated promoter by methylation specific PCR. Biochem. Biophys. Res. Commun. 340: 268-276. (Pubitemid 41827676)
62. Zhuang, J., S. F. Hawkins, M. A. Glenn, K. Lin, G. G. Johnson, A. Carter, J. C. Cawley, and A. R. Pettitt. 2010. Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition. Haematologica 95: 110-118.
63. Nyåkern, M., A. Cappellini, I. Mantovani, and A. M. Martelli. 2006. Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol. Cancer Ther. 5: 1559-1570. (Pubitemid 44070493)
64. Engedal, N., and H. K. Blomhoff. 2003. Combined action of ERK and NF kappa B mediates the protective effect of phorbol ester on Fas-induced apoptosis in Jurkat cells. J. Biol. Chem. 278: 10934-10941. (Pubitemid 36792640)
65. Zaman, S. N., M. E. Resek, and S. M. Robbins. 2008. Dual acylation and lipid raft association of Src-family protein tyrosine kinases are required for SDF-1/ CXCL12-mediated chemotaxis in the Jurkat human T cell lymphoma cell line. J. Leukoc. Biol. 84: 1082-1091.
66. Arsenault, R. J., S. Jalal, L. A. Babiuk, A. Potter, P. J. Griebel, and S. Napper. 2009. Kinome analysis of Toll-like receptor signaling in bovine monocytes. J. Recept. Signal Transduct. Res. 29: 299-311.
67. Jalal, S., R. Arsenault, A. A. Potter, L. A. Babiuk, P. J. Griebel, and S. Napper. 2009. Genome to kinome: species-specific peptide arrays for kinome analysis. Sci. Signal. 2: pl1.
68. Goldberg, J. M., L. B. Silverman, D. E. Levy, V. K. Dalton, R. D. Gelber, L. Lehmann, H. J. Cohen, S. E. Sallan, and B. L. Asselin. 2003. Childhood T-cell acute lymphoblastic leukemia: the Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J. Clin. Oncol. 21: 3616-3622. (Pubitemid 46594054)
69. Jørgensen, C., A. Sherman, G. I. Chen, A. Pasculescu, A. Poliakov, M. Hsiung, B. Larsen, D. G. Wilkinson, R. Linding, and T. Pawson. 2009. Cell-specific information processing in segregating populations of Eph receptor ephrinexpressing cells. Science 326: 1502-1509.
70. Sarbassov, D. D., D. A. Guertin, S. M. Ali, and D. M. Sabatini. 2005. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098-1101. (Pubitemid 40262113)
71. Rincón, M., and G. Pedraza-Alva. 2003. JNK and p38 MAP kinases in CD4+ and CD8+ T cells. Immunol. Rev. 192: 131-142. (Pubitemid 36613329)
72. Sohn, S. J., J. Thompson, and A. Winoto. 2007. Apoptosis during negative selection of autoreactive thymocytes. Curr. Opin. Immunol. 19: 510-515. (Pubitemid 47464913)
73. Manning, A. M., and R. J. Davis. 2003. Targeting JNK for therapeutic benefit: from junk to gold? Nat. Rev. Drug Discov. 2: 554-565. (Pubitemid 37361747)
74. Zamoyska, R., A. Basson, A. Filby, G. Legname, M. Lovatt, and B. Seddon. 2003. The influence of the src-family kinases, Lck and Fyn, on T cell differentiation, survival and activation. Immunol. Rev. 191: 107-118. (Pubitemid 36398852)
75. Cross, D. A., D. R. Alessi, P. Cohen, M. Andjelkovich, and B. A. Hemmings. 1995. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378: 785-789. (Pubitemid 26004411)
76. Holen, H. L., K. Nustad, and H. C. Aasheim. 2010. Activation of EphA receptors on CD4+CD45RO+ memory cells stimulates migration. J. Leukoc. Biol. 87: 1059-1068.
77. Luo, H., G. Yu, Y. Wu, and J. Wu. 2002. EphB6 crosslinking results in costimulation of T cells. J. Clin. Invest. 110: 1141-1150. (Pubitemid 35215895)
78. Gurniak, C. B., and L. J. Berg. 1996. A new member of the Eph family of receptors that lacks protein tyrosine kinase activity. Oncogene 13: 777-786. (Pubitemid 26312905)
79. Matsuoka, H., N. Iwata, M. Ito, M. Shimoyama, A. Nagata, K. Chihara, S. Takai, and T. Matsui. 1997. Expression of a kinase-defective Eph-like receptor in the normal human brain. Biochem. Biophys. Res. Commun. 235: 487-492. (Pubitemid 27326506)
80. Truitt, L., T. Freywald, J. DeCoteau, N. Sharfe, and A. Freywald. 2010. The EphB6 receptor cooperates with c-Cbl to regulate the behavior of breast cancer cells. Cancer Res. 70: 1141-1153.
81. Yang, N. Y., C. Fernandez, M. Richter, Z. Xiao, F. Valencia, D. A. Tice, and E. B. Pasquale. 2011. Crosstalk of the EphA2 receptor with a serine/threonine phosphatase suppresses the Akt-mTORC1 pathway in cancer cells. Cell Signal 23: 201-212.
82. Safa, A. R., T. W. Day, and C. H. Wu. 2008. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. Curr. Cancer Drug Targets 8: 37-46. (Pubitemid 351237908)
83. Paganin, M., and A. Ferrando. 2011. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia. Blood Rev. 25: 83-90.
84. Heath, V. L., and R. Bicknell. 2009. Anticancer strategies involving the vasculature. Nat. Rev. Clin. Oncol. 6: 395-404.
85. Esteva, F. J., D. Yu, M. C. Hung, and G. N. Hortobagyi. 2010. Molecular predictors of response to trastuzumab and lapatinib in breast cancer. Nat. Rev. Clin. Oncol. 7: 98-107.